0001193125-22-150303.txt : 20220513 0001193125-22-150303.hdr.sgml : 20220513 20220513172715 ACCESSION NUMBER: 0001193125-22-150303 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20220512 ITEM INFORMATION: Termination of a Material Definitive Agreement ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20220513 DATE AS OF CHANGE: 20220513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Akebia Therapeutics, Inc. CENTRAL INDEX KEY: 0001517022 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208756903 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36352 FILM NUMBER: 22924156 BUSINESS ADDRESS: STREET 1: 245 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-871-2098 MAIL ADDRESS: STREET 1: 245 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 8-K 1 d721313d8k.htm 8-K 8-K
false 0001517022 0001517022 2022-05-12 2022-05-12

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 12, 2022

 

 

AKEBIA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-36352   20-8756903

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

245 First Street

Cambridge, Massachusetts

  02142
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 871-2098

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.00001 per share   AKBA   The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Item 1.02

Termination of a Material Definitive Agreement.

International Collaboration and License Agreement with Otsuka Pharmaceutical Co. Ltd.

On May 12, 2022, Akebia Therapeutics, Inc. (the “Company”) received written notice from Otsuka Pharmaceutical Co. Ltd. (“Otsuka”) that Otsuka has elected to terminate the Collaboration and License Agreement dated April 25, 2017 (the “Otsuka International Agreement”). Otsuka exercised its right to terminate the Otsuka International Agreement for convenience and, in accordance with the terms of the Otsuka International Agreement and the notice of termination, the termination will be effective on May 13, 2023 (the “International Termination Effective Date”).

Under the terms of the Otsuka International Agreement, the Company granted to Otsuka an exclusive, sublicensable license under certain intellectual property controlled by the Company to develop and commercialize vadadustat, the Company’s lead investigational product candidate for which it received a complete response letter from the U.S. Food and Drug Administration (the “FDA”) in March 2022, in Europe, Russia, China, Canada, Australia, the Middle East and certain other territories (collectively, the “Otsuka International Territory”). Additionally, under the terms of the Otsuka International Agreement, the Company is responsible for leading the development of vadadustat, and Otsuka has the sole responsibility, at its own cost, for the commercialization of vadadustat in the Otsuka International Territory, subject to the approval by the relevant regulatory authorities.

Otsuka submitted a Marketing Authorization Application for vadadustat for the treatment of anemia due to chronic kidney disease in adult patients on dialysis and not on dialysis to the European Medicines Agency (the “EMA”) in October 2021 and submitted applications for regulatory approval in the United Kingdom, Switzerland and Australia in March 2022. The Company has supported, and intends to continue to support, the regulatory approval process in those jurisdictions.

The foregoing summary of the terms of the Otsuka International Agreement is qualified in its entirety by reference to the full text of the Otsuka International Agreement, which was filed with the U.S. Securities and Exchange Commission (the “SEC”) as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q (001-36352) on August 8, 2017 and is incorporated by reference herein.

U.S. Collaboration and License Agreement with Otsuka Pharmaceutical Co. Ltd.

On May 12, 2022, the Company also received written notice from Otsuka that Otsuka has elected to terminate the Collaboration and License Agreement dated December 18, 2016 (the “Otsuka U.S. Agreement”). Otsuka exercised its right to terminate the Otsuka U.S. Agreement for convenience, and in accordance with the terms of the Otsuka U.S. Agreement and the notice of termination, the termination will be effective on May 13, 2023 (the “U.S. Termination Effective Date”). In addition and in the alternative, Otsuka has provided notice of termination for alleged material breaches by the Company under the Otsuka U.S. Agreement, which alleged breaches, if not cured, could result in an earlier termination of the Otsuka U.S. Agreement effective as early as June 12, 2022. However, the Company disagrees with, and intends to dispute, Otsuka’s allegations of material breach and does not believe that Otsuka has a right to terminate the Otsuka U.S. Agreement for material breach, and accordingly believes that the termination of the Otsuka U.S. Agreement should not be effective prior to the U.S. Termination Effective Date.

The Otsuka U.S. Agreement provides that that Company will co-commercialize vadadustat in the United States with Otsuka, subject to the approval of vadadustat by the FDA, and that the Company would control and retain final decision-making authority with respect to certain matters. The Company is responsible for leading the development of vadadustat. Under the Otsuka U.S. Agreement and the Otsuka International Agreement, Otsuka currently funds 80% of our global development costs for vadadustat.

In addition, as a result of the termination of the Otsuka U.S. Agreement as well as the Otsuka International Agreement, the Company will regain exclusive rights to develop and commercialize vadadustat worldwide, other than in Japan and certain other Asian countries, which territory is the subject of the Company’s Collaboration Agreement with Mitsubishi Tanabe Pharma Corporation.

The foregoing summary of the terms of the Otsuka U.S. Agreement is qualified in its entirety by reference to the full text of the Otsuka U.S. Agreement, which was filed with the SEC as Exhibit 10.26 to the Company’s Annual Report on Form 10-K (001-36352) on March 6, 2017 and is incorporated by reference herein.


Item 3.01

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On May 12, 2022, the Company received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock, par value $0.00001 per share (the “Common Stock”), had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”).

In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the “Compliance Period Rule”), the Company has been provided a period of 180 calendar days, or until November 8, 2022 (the “Compliance Date”), to regain compliance with the Bid Price Requirement. If, at any time before the Compliance Date, the bid price for the Common Stock closes at $1.00 or more for a minimum of 10 consecutive business days as required under the Compliance Period Rule (unless the Staff exercises its discretion to extend this ten-day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H)), the Staff will provide written notification to the Company that it has regained compliance with the Bid Price Requirement.

If the Company does not regain compliance with the Bid Price Requirement by the Compliance Date, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company would need to transfer the listing of the Common Stock to the Nasdaq Capital Market, provided that it meets the continued listing requirement for the market value of publicly held shares and all other initial listing standards, with the exception of the Bid Price Requirement. To effect such a transfer, the Company would also need to pay an application fee to Nasdaq and will need to provide written notice to the Staff of its intention to cure the deficiency during the additional compliance period by effecting a reverse stock split, if necessary. As part of its review process, the Staff will make a determination of whether it believes the Company will be able to cure this deficiency.

Should the Staff conclude that the Company will not be able to cure the deficiency, or should the Company determine not to submit an application for transfer to the Nasdaq Capital Market or notify the Staff of its intention to cure the deficiency, the Staff will provide written notification to the Company that the Common Stock will be subject to delisting. At that time, the Company may appeal the Staff’s delisting determination to a Nasdaq Listing Qualifications Panel (the “Panel”). However, there can be no assurance that, if the Company receives a delisting notice and appeals the delisting determination by the Staff to the Panel, such appeal would be successful.

The Company intends to monitor the closing bid price of the Common Stock and may, if appropriate, consider available options to regain compliance with the Bid Price Requirement, which could include seeking to effect a reverse stock split. However, there can be no assurance that the Company will be able to regain compliance with the Bid Price Requirement.

Forward-Looking Statements

Statements in this Current Report on Form 8-K regarding the Company’s strategy, plans, prospects, expectations, beliefs, intentions and goals are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended. The terms “believe,” “expect,” “potential,” “will,” “continue,” “intend,” derivatives of these words, and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various risks, uncertainties and other factors, including those identified under the heading “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, and other filings that the Company may make with the SEC in the future. These forward-looking statements (except as otherwise noted) speak only as of the date of this Current Report on Form 8-K, and, except as required by law, the Company does not undertake, and specifically disclaims, any obligation to update any forward-looking statements contained in this Current Report on Form 8-K.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      AKEBIA THERAPEUTICS, INC.
Date: May 13, 2022     By:  

/s/ John P. Butler

    Name:   John P. Butler
    Title:   President and Chief Executive Officer
EX-101.SCH 2 akba-20220512.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 akba-20220512_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 akba-20220512_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
May 12, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001517022
Document Type 8-K
Document Period End Date May 12, 2022
Entity Registrant Name AKEBIA THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-36352
Entity Tax Identification Number 20-8756903
Entity Address, Address Line One 245 First Street
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02142
City Area Code (617)
Local Phone Number 871-2098
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.00001 per share
Trading Symbol AKBA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 6 d721313d8k_htm.xml IDEA: XBRL DOCUMENT 0001517022 2022-05-12 2022-05-12 false 0001517022 8-K 2022-05-12 AKEBIA THERAPEUTICS, INC. DE 001-36352 20-8756903 245 First Street Cambridge MA 02142 (617) 871-2098 false false false false Common Stock, par value $0.00001 per share AKBA NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://akebia.com//20220512/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d721313d8k.htm akba-20220512.xsd akba-20220512_lab.xml akba-20220512_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d721313d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d721313d8k.htm" ] }, "labelLink": { "local": [ "akba-20220512_lab.xml" ] }, "presentationLink": { "local": [ "akba-20220512_pre.xml" ] }, "schema": { "local": [ "akba-20220512.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "akba", "nsuri": "http://akebia.com/20220512", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d721313d8k.htm", "contextRef": "duration_2022-05-12_to_2022-05-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://akebia.com//20220512/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d721313d8k.htm", "contextRef": "duration_2022-05-12_to_2022-05-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://akebia.com//20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://akebia.com//20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://akebia.com//20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://akebia.com//20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://akebia.com//20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://akebia.com//20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://akebia.com//20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://akebia.com//20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://akebia.com//20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://akebia.com//20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://akebia.com//20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://akebia.com//20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://akebia.com//20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://akebia.com//20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://akebia.com//20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://akebia.com//20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://akebia.com//20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://akebia.com//20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://akebia.com//20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://akebia.com//20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://akebia.com//20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://akebia.com//20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 13 0001193125-22-150303-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-150303-xbrl.zip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end